Nasopharyngeal carcinoma prognosis predicted by PD-L1 overexpression

  • Liu X & al.
  • Front Oncol
  • 1 Jan 2019

  • curated by Brian Richardson, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • High expression of programmed cell death ligand-1 (PD-L1) is associated with poor survival outcomes of patients with nasopharyngeal carcinoma (NPC), according to a systematic review and meta-analysis.

Why this matters

  • Prognostic biomarkers can help guide patient management.

Key results

  • High PD-L1 expression was associated with reduced OS (9 studies; HR, 1.48; P=.049).
    • In subgroup analysis, PD-L1 expression was associated with OS in patients with stage II-III disease (P=.016), stage III-IV disease (P=.049), and recurrent/previously treated patients (P=.044).
  • High PD-L1 expression was not significantly associated with DFS (6 studies; HR, 1.51; P=.162), distant metastasis-free survival (3 studies; HR, 1.75; P=.277), or local recurrence-free survival (2 studies; HR, 0.67; P=.756).

Study design

  • 11 studies (1315 patients with NPC) were included in the meta-analysis.
  • Funding: None disclosed.

Limitations

  • Heterogeneity between included studies.